InVivo closes out dismal week with big loss

Make no mistake, it was not a good week for shares of InVivo Therapeutics (NVIV.OB) which fell 18% on the day.

The shares are off some 66% from Monday's intraday high.

"The FDA’s increasing caution over biological grafts has been evident for a while, but seems to have caught NVIV investors by surprise," SA contributor EP Vantage said, in an article published Thursday afternoon.

Previously: NVIV plunges on update to clinical plan

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs